NCCN Quick Guide™ | Chronic Myeloid Leukemia

2 of 2 NCCN QUICK GUIDE tm Chronic Myeloid Leukemia, 2018 PAT-N-1019-1017 What are the treament options for accelerated CML? „„ Clinical trial. 36 „„ TKI (imatinib, dasatinib, nilotinib, bosutinib, ponatinib). „„ Omacetaxine. „„ For long-term cancer control, an HCT is needed. What are the treatment options for blast CML? „„ Treatment options are based on the main cell type—lymphoid or myeloid. 37 „„ A clinical trial is an option for either type. „„ TKI (imatinib, dasatinib, nilotinib, bosutinib, ponatinib) and chemotherapy. The type of chemotherapy depends on main cell type. „„ TKI with a steroid for lymphoid cell type. „„ TKI alone for myeloid cell type. „„ For long-term control, an HCT is needed. What are the options after HCT? „„ If treatment worked, think about taking a TKI for a year 38 „„ If treatment did not work, options include TKI, TKI + donor lymphocyte infusion, omacetaxine, and a clinical trial. What are some tips for deciding treatment? Ask your doctors many questions. Also, you can get a second opinion, attend support groups, and compare pros and cons. 41 NCCN Guidelines for Patients ® Page Number Ü - for Patients | - for Clinicians DONATE NOW The NCCN QUICK GUIDE tm series and NCCN Guidelines for Patients ® are supported by charitable donations made to the NCCN Foundation ® . For more details and the full library of patient and caregiver resources, visit